Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML

Therapy directed against oncogenic FLT3 has been shown to induce response in patients with acute myeloid leukemia (AML), but these responses are almost always transient. To address the mechanism of FLT3 inhibitor resistance, we generated two resistant AML cell lines by sustained treatment with the F...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncogene
Autors principals: Lindblad, O, Cordero, E, Puissant, A, Macaulay, L, Ramos, A, Kabir, N N, Sun, J, Vallon-Christersson, J, Haraldsson, K, Hemann, M T, Borg, Å, Levander, F, Stegmaier, K, Pietras, K, Rönnstrand, L, Kazi, J U
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5399143/
https://ncbi.nlm.nih.gov/pubmed/26999641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2016.41
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars